SHARE
Press Release
Back
Products

October 10, 2023

Evonik introduces the world’s first carbon-fiber reinforced PEEK filament for long-term 3D printed medical implants

  • Evonik unveils the world’s first carbon-fiber reinforced PEEK filament for 3D printed medical implants.
  • The filament offers 12% or 20% carbon-fiber content, customizable for specific implant strength and flexibility.
  • Key benefits include bio-compatibility, alignment-controlled fibers, and suitability for metal allergy patients.
  • Evonik aims to accelerate medical innovation with expertise in polymer chemistry and manufacturing technologies.
  • The VESTAKEEP® portfolio is comprehensive, covering long-term and short-term implant-grade PEEK filaments.

Evonik introduces the world’s first carbon-fiber reinforced PEEK filament for 3D printed medical implants. With 12% or 20% carbon-fiber content, the VESTAKEEP® filament offers adaptability for implant needs. This material combines high strength, ductility, and low weight, providing a metal-free alternative for advanced implants. Usable in standard FFF/FDM 3D printers, it supports patient-specific implant creation and reflects Evonik’s commitment to pioneering solutions for a better tomorrow.

VESTAKEEP® filament with 12% or 20% carbon-fiber content for adaptability to requirements of implants

  • VESTAKEEP® filament with 12% or 20% carbon-fiber content for adaptability to requirements of implants
  • Alignment of carbon-fiber can be controlled during the 3D printing process
  • Ideal balance of high strength, ductility and low weight makes PEEK an ideal metal-free alternative for implants

Marl, Germany. Evonik is introducing a new carbon-fiber reinforced PEEK filament, for use in 3D printed medical implants. This smart biomaterial can be processed in common extrusion-based 3D printing technologies such as fused filament fabrication (FFF). The specialty chemicals company will present the new product for the first time at coming next medical technology and 3D printing related trade shows.

Carbon-fiber reinforced PEEK for 3D printed medical implants

Dubbed VESTAKEEP® iC4612 3DF and VESTAKEEP® iC4620 3DF, the two available filaments feature 12% and 20% carbon fiber content, respectively. The two grades offer a choice of material depending on the required strength and flex properties of 3D printed implants such as bone plates and other reconstructive prostheses.

Evonik’s VESTAKEEP® iC4612 3DF and VESTAKEEP® iC4620 3DF offer great benefits from the strength from the high carbon-fiber content, matched with the ductility of its PEEK component. Additional product benefits include the ability to define the alignment of the carbon fibers during the 3D printing process, high bio-compatibility for metal allergy-patients, and the no x-rays artifacts.

Designing smart biomaterials for a life beyond limits

“By introducing the world’s first carbon-fiber reinforced PEEK filament for long-term medical implants, we continue to design biomaterials that open up new possibilities in today’s medical technology for patient-specific treatment,” says Marc Knebel, Head of Medical Systems at Evonik. “As passionate experts with decades of experience in polymer chemistry, we combine a unique set of competencies in materials science, manufacturing technologies and regulatory expertise to customers to accelerate time-to-market of new medical technologies for people's lives beyond limits.”

With a diameter of 1.75 mm, VESTAKEEP® iC4612 3DF and VESTAKEEP® iC4620 3DF are supplied on 500g and 1,000g spools that can be used directly in standard FFF/FDM 3D printers for PEEK materials. The filament is subjected to strict quality management for medical materials.

"No other application field showcases more the advantages of 3D printing, such as individualization or design freedom, than medical technology," says Knebel. “In trauma applications, for instance, 3D printed solutions offer an enormous time advantage over traditionally manufactured medical devices. It is conceivable that patient-specific solutions can be manufactured within two or three days, significantly improving the recovery phase.”

Marc Knebel, Head of Medical Systems at Evonik.

Comprehensive portfolio of PEEK filaments for medical technology

Over the last five years, Evonik has been gradually developing new PEEK-based filaments for medical 3D printing applications and thus setting material quality standards in medical technology with additive manufacturing. The current portfolio includes different grades for long-term and short-term body contact applications:

Long-term body contact applications:

  • VESTAKEEP® i4 3DF - Implant grade (long-term)
  • VESTAKEEP® i4 3DF-T - Test and development grade
  • VESTAKEEP® iC4800 3DF - Osteoconductive implant grade
  • VESTAKEEP® iC4612 3DF – Carbon-fiber reinforced (12%) implant grade
  • VESTAKEEP® iC4620 3DF – Carbon-fiber reinforced (20%) implant grade

Short-term body contact applications:

  • VESTAKEEP® Care M40 3DF - Medical care grade

Evonik has been the world's leading manufacturer of smart biomaterials for additive manufacturing technologies for more than 20 years. The specialty chemicals company offers the industry's most extensive portfolio of 3D-printable biomaterials for medical technology, which can be used to manufacture medical device parts designed for temporary and permanent body contact. In addition to PEEK-based filaments of the VESTAKEEP® brand, the portfolio includes the RESOMER® line of bioresorbable filaments, powders and granules for implantable medical devices.

First carbon-fiber reinforced PEEK filament for long-term 3D printed medical implants

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. The common motivation of the approximately 31,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.